In fact, we demonstrated recently that soluble CD26 levels (sCD26) were a much better serum marker for the detection of CRC metastasis or tumor recurrence compared to other markers in clinical use, such as CEA, CA-19.9, or CA-72.4 (De Chiara et al., 2014). This evidence concerns the gene DPP4 and neoplasm.